A biotechnology firm, 9 Meters Biopharma (NMTR), focuses on patients with rare diseases and unmet needs. The company’s portfolio contains drug candidates with short bowel syndrome (SBS) and celiac disease.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Recent Scores
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
The Company with a Market Cap of 217.64 M was up 27.53% to 1.0700 at yesterday’s close. It stayed up even expanded 23.36% to 1.32 in the extended session. During the last 52-weeks’ time,the Company stock price ranged from $0.3700 to $1.2200. In the previous trading session,17,412,006 shares of NMTR changed hands compared to its average volume of 3,740,066.
Latest Updates
There is no update available or revealed by the company itself in the last 24 hours. However, developments in the previous couple of months have put the stock in positive territory.
• On December 21, 2020, an agreement was revealed between the 9 Meters Biopharma and the European Biomedical Research Institute of Salerno (EBRIS), led to the advancement of a study on larazotide injections in healthy volunteers to evaluate larazotide safety and tolerability in lung tissue.
• On December 16, 2020, the company announced the closing of its previously announced underwritten public offering of 53,076,924 shares of its common stock at a price to the public of $0.65.
• On December 9, 2020,NMTR said that a proprietary long-acting agonist of the GLP-2 receptor had been granted orphan drug designation by the Food and Drug Administration (FDA) as a preventative of acute graft versus host disease.